SCHEMBL257495

SCHEMBL257495

CCn1c(C(=O)c2ccccc2)cc(C)c1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 2/20 0.45
FNTB P49356 2/20 0.45
AKR1C3 P42330 2/20 0.40
RAB9A P51151 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 4/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
POLB P06746 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
ALOX12 P18054 1/20 0.39
RECQL P46063 1/20 0.39
TSHR P16473 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ATM Q13315 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SRD5A2 P31213 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15197144 0.90 FNTA (0.41) FNTAFNTBRAB9AHSD17B10ALDH1A1
SCHEMBL257496 0.87 ALDH1A1 (0.48) RAB9AHSD17B10ALDH1A1KMT2AMEN1
SCHEMBL10046853 0.80 FNTA (0.44) FNTAFNTBAKR1C3HSD17B10ALDH1A1
SCHEMBL13679134 0.74 RAB9A (0.46) FNTAFNTBRAB9AHSD17B10ALDH1A1
SCHEMBL256764 0.74 ALDH1A1 (0.49) RAB9AHSD17B10ALDH1A1KMT2AMEN1
SCHEMBL891105 0.73 KDM4E (0.44) HSD17B10ALDH1A1KMT2AMEN1POLB
SCHEMBL11565034 0.72 NOTUM (0.53) AKR1C3RAB9AHSD17B10ALDH1A1KMT2A
SCHEMBL15197093 0.72 MAPT (0.42) FNTAFNTBHSD17B10ALDH1A1KMT2A
SCHEMBL7677999 0.71 PTGS2 (0.52) RAB9AHSD17B10ALDH1A1KMT2AMEN1
SCHEMBL10939276 0.69 ALDH1A1 (0.47) FNTAFNTBALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 FNTA 3532/4885FNTB 2106/4885AKR1C3 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.